Knockdown of EGFR inhibits growth and invasion of gastric cancer cells

Cancer Gene Therapy

Volumn 21, Issue 11, 2014, Pages 491-497

  Zhen, Y ^a   Guanghui, L ^a   Xiefu, Z ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; LENTIVIRUS VECTOR; PROTEIN KINASE B; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; GASTRIC CANCER CELL LINE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TISSUE MICROARRAY; TUMOR INVASION; WESTERN BLOTTING; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; LENTIVIRINAE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL CULTURE;

BLOTTING, WESTERN; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 84927177569     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.55     Document Type: Article

References (40)

1. Luo HQ, Han L, Jiang Y. Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer. Asian Pac J Cancer Prev 2014; 15(13): 5343-5348.
2. Lyu X, Huang J, Liu J, Wang W, Su Y, Zhang W et al. Detection and significance of epidermal growth factor receptor mutation in esophageal, esophagogastric junction and gastric cancers. Zhonghua Zhong Liu Za Zhi 2014; 36(5): 346-350 Chinese.
3. Li Y, Tan BB, Zhao Q, Fan LQ, Wang D, Liu Y. ZNF139 promotes tumor metastasis by increasing migration and invasion in human gastric cancer cells. Neoplasma 2014; 61(3): 291-298.
4. Liu G, Jiang C, Li D, Wang R, Wang W. MiRNA-34a inhibits EGFR-signalingdependent MMP7 activation in gastric cancer. Tumour Biol 2014, 36-45.
5. Smyth EC, Sclafani F, Cunningham D. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 2014; 7: 1001-1014.
6. Rolfo C, Bronte G, Sortino G, Papadimitriou K, Passiglia F, Fiorentino E et al. The role of targeted therapy for gastrointestinal tumors. Expert Rev Gastroenterol Hepatol 2014; 7: 1-11.
7. Guan SS, Chang J, Cheng CC, Luo TY, Ho AS, Wang CC et al. Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. Oncotarget 2014; 5(13): 4868-4880.
8. Luo BH, Xiong F, Wang JP, Li JH, Zhong M, Liu QL et al. Epidermal growth factorlike domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. PLoS One 2014; 9: 332-343.
9. Vaiopoulos AG, Kostakis ID, Gkioka E, Athanasoula KCh, Pikoulis E, Papalambros A et al. Detection of circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay. Anticancer Res 2014; 34(6): 3083-3092.
10. Choi MR, An CH, Chung YJ, Choi YJ, Yoo NJ, Lee SH. Mutational and expressional analysis of ERBB3 gene in common solid cancers. APMIS 2014; 23: 113-124.
11. Musiani D, Konda JD, Pavan S, Torchiaro E, Sassi F, Noghero A et al. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy. FASEB J 2014; 23: 456-468.
12. Xu L, Qu X, Li H, Li C, Liu J, Zheng H et al. Src/caveolin-1-regulated EGFR activation antagonizes TRAIL-induced apoptosis ingastric cancer cells. Oncol Rep 2014; 32(1): 318-324.
13. Aprile G, Giampieri R, Bonotto M, Bittoni A, Ongaro E, Cardellino GG et al. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opin Investig Drugs 2014; 23(7): 925-942.
14. Kurokawa Y, Matsuura N, Kawabata R, Nishikawa K, Ebisui C, Yokoyama Y et al. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann Surg Oncol 2014; 11: 432-441.
15. Nielsen TO, Friis-Hansen L, Poulsen SS, Federspiel B, Sorensen BS. Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4. PLoS One 2014; 9(4): e94606.
16. Wei J, Zhao ZX, Li Y, Zhou ZQ, You TG. Cortactin expression confers a more malignant phenotype to gastric cancer SGC-7901 cells. World J Gastroenterol 2014; 20(12): 3287-3300.
17. Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L et al. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 2014; 5(8): 2276-2292.
18. Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev 2014; 40(6): 770-780.
19. Naruke A, Azuma M, Takeuchi A, Ishido K, Katada C, Sasaki T et al. Comparison of site-specific gene expression levels in primary tumors and synchronous lymph node metastases in advanced gastric cancer. Gastric Cancer 2014; 9: 116-124.
20. Jiang L, Chen Y, Sang J, Li Y, Lan T, Wang Y et al. Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells. Biomed Rep 2013; 1(3): 399-404.
21. Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer 2014; 14: 783-797.
22. Zhang J, Cao J, Li J, Zhang Y, Chen Z, Peng W et al. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. J Hematol Oncol 2014; 7: 22.
23. Ye B, Jiang LL, Xu HT, Zhou DW, Li ZS. Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis. Int J Immunopathol Pharmacol 2012; 25: 627-636.
24. Xie J, Chen M, Zhou J, Mo MS, Zhu LH, Liu YP et al. miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol Rep 2014; 31(4): 1715-1722.
25. Jiang L, Chen Y, Li Y, Lan T, Wu M, Wang Y et al. Type II cGMP-dependent protein kinase inhibits ligand-induced activation of EGFR ingastric cancer cells. Mol Med Rep 2014; 9(4): 1405-1409.
26. Chaturvedi R, Asim M, Piazuelo MB, Yan F, Barry DP, Sierra JC et al. Activation of EGFR and ERBB2 by Helicobacter pylori results in survival of gastricepithelial cells with DNA damage. Gastroenterology 2014146 7: 1739.e14-1751.e14.
27. Gala K, Chandarlapaty S. Molecular pathways: HER3 targeted therapy. Clin Cancer Res 2014; 20(6): 1410-1416.
28. Agaimy A, Rau TT, Hartmann A, Stoehr R. SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. Am J Surg Pathol 2014; 38(7): 910-920.
29. Tajiri R, Ooi A, Fujimura T, Dobashi Y, Oyama T, Nakamura R et al. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization. Hum Pathol 2014; 45(4): 725-734.
30. Shi M, Shi H, Ji J, Cai Q, Chen X, Yu Y et al. Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status. Curr Cancer Drug Targets 2014; 16: 763-784.
31. Terragni R, Casadei Gardini A, Sabattini S, Bettini G, Amadori D, Talamonti C et al. EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model? PLoS One 2014; 9(1): e85388.
32. Zhang J, Zhan Z, Wu J, Zhang C, Yang Y, Tong S et al. Relationship between EGF, TGFA, and EGFR gene polymorphisms and traditional Chinese medicine ZHENG in gastric cancer. Evid Based Complement Alternat Med 2013; 2013: 731071.
33. Zhang L, Zhao G, Hou Y, Zhang J, Hu J, Zhang K. The experimental study on the treatment of cytokine-induced killer cells combined with EGFR monoclonal antibody against gastric cancer. Cancer Biother Radiopharm 2014; 29(3): 99-107.
34. Hong L, Han Y, Brain L. The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer. Expert Rev Gastroenterol Hepatol 2014; 8(1): 111-117.
35. Feng D, Ma Y, Liu J, Xu L, Zhang Y, Qu J et al. Cbl-b enhances sensitivity to 5-fluorouracil via EGFR-and mitochondria-mediated pathways in gastric cancer cells. Int J Mol Sci 2013; 14(12): 24399-24411.
36. Zhang EB, Han L, Yin DD, Kong R, De W, Chen J. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. Med Oncol 2014; 31(5): 914.
37. Aydin K, Okutur SK, Bozkurt M, Turkmen I, Namal E, Pilanci K et al. Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: a pilot study. Oncol Lett 2014; 7(1): 255-259.
38. Ito A, Ito Y, Matsushima S, Tsuchida D, Ogasawara M, Hasegawa J et al. New whole-body multimodality imaging of gastric cancer peritoneal metastasis combining fluorescence imaging with ICG-labeled antibody and MRI in mice. Gastric Cancer 2014; 17(3): 497-507.
39. Pang Q, Ge J, Shao Y, Sun W, Song H, Xia T et al. Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. Tumour Biol 2014; 35(6): 5441-5447.
40. Wang Y, Feng X, Jia R, Liu G, Zhang M, Fan D et al. Microarray expression profile analysis of long non-coding RNAs of advanced stage human gastric cardia adenocarcinoma. Mol Genet Genomics 2014; 289(3): 291-302.